NestlÉ health science agrees to acquire global rights to vowst®, product it launched in june 2023

Transaction ensures nestlÉ health science will continue to commercialize the product bridgewater, n.j. , june 6, 2024 /prnewswire/ -- seres therapeutics, inc. (nasdaq: mcrb), announced today that it has agreed to a non-binding memorandum of understanding with nestlÉ health science in which nestlÉ health science will acquire certain tangible and intangible assets associated with vowst (fecal microbiota spores, live-brpk) capsules.
MCRB Ratings Summary
MCRB Quant Ranking